GYREGyre Therapeutics, Inc.
$6.76-7.0% 1Y
$6.76
$5.5652 weeks$8.87
GYRE in its own filings
GYRE's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
511
Events found in the filings · across 1,601 filings · the record starts in 2006
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 1, 2026
Most recent filing · Form 8-K
- Record starts
- May 25, 2006
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 6, 2026
- Change in certifying accountant2 occurrences
- 2023-11-02
- Delisting notice / listing-rule failure8 occurrences
- 2024-07-05
- SEC comment-letter activity38 occurrences
- 2024-11-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 20261 September 2026 A Global Innovator Expanding And Reinventing Protein Degrader.Regulation FD disclosure · press release
- Aug 26, 20261 August 2026 Building A New Protein Degrader Company For Unmet Medical Needs.Regulation FD disclosure · press release
- Aug 7, 2026Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update.Earnings release · press release
- Jul 16, 2026On July 10, 2026, the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1 …Director or officer change · Form 8-K
- Jul 15, 2026To the Shareholders and the Board of Directors of Cullgen Inc.Earnings release · press release
- Jun 2, 2026A Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory.Regulation FD disclosure · press release
- May 14, 2026A Fully-integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory.Regulation FD disclosure · press release
- May 12, 2026Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment.Regulation FD disclosure · press release
- May 7, 2026Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update.Earnings release · press release
- May 4, 2026Agreement and Plan of Merger and Reorganization On May 4, 2026 (the “Closing Date”), Gyre Therapeutics, Inc., a Delaware corporation (the “Company” or “Gyre”), consummated the previously announced acquisition of Cullgen Inc., a Delaware corporation (“Cullgen”), in accordance with the terms of the Agreement and Plan of …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…